Is medical marijuana safe for testing programs to accept

The federal-state scheduling conflict in operational terms

Marijuana — defined under the Controlled Substances Act as Cannabis sativa containing more than 0.3 percent delta-9 THC by dry weight — is currently a Schedule I controlled substance under federal law. The DEA scheduling page maintains the current regulatory status, which programs should reference rather than rely on third-party summaries. Schedule I designation means that under federal law cannabis has no accepted medical use, despite the existence of state medical-cannabis programs in a substantial majority of U.S. states.

Programs operating under any federal framework — DOT-regulated transportation, federal contractors subject to the Drug-Free Workplace Act, federal grantees, federally regulated nuclear and aviation roles, federal employees themselves — are bound by the federal scheduling. State medical-cannabis authorization does not modify federal testing obligations. DOT Office of Drug and Alcohol Policy and Compliance guidance has been explicit and repeated on this point: medical recommendations for marijuana are not a legitimate medical explanation for a confirmed THC positive under DOT 49 CFR Part 40.

Non-federal employers operating under state-specific workplace-testing statutes face a more variable landscape. Some states require employer accommodation of medical-cannabis cardholders; others explicitly permit employer enforcement against THC positives regardless of medical authorization; many states have litigation pending or recent jurisprudential shifts. The operational implication for multi-state programs is that a single uniform testing policy may produce different defensibility outcomes in different jurisdictions. Counsel-driven state-by-state policy review is the standard recommendation.

How medical-review officers handle medical-cannabis recommendations

The medical-review officer (MRO) function in regulated workplace testing is to evaluate confirmed laboratory-positive results against legitimate medical explanations. For most non-cannabis analytes, a current valid prescription from a treating physician constitutes an MRO defense — a patient with a documented oxycodone prescription, for example, has a legitimate medical explanation for a confirmed oxycodone-positive result, and the MRO reports the test as negative to the employer.

For THC, the MRO defense pathway operates differently under DOT and most federal frameworks. The DOT Office of Drug and Alcohol Policy and Compliance has been explicit that a state medical-cannabis recommendation does not constitute a legitimate medical explanation for a confirmed marijuana-positive result. The MRO is required to report the result as positive to the employer regardless of state authorization. The reasoning is grounded in the federal Schedule I status — federal regulatory frameworks treat all THC use as illegal under federal law, and state medical authorization does not modify that status.

For non-DOT and non-federal employers, MRO practice varies by employer policy and applicable state law. Some employers instruct their MRO to apply the DOT standard uniformly; others permit MRO acceptance of state medical-cannabis recommendations under defined conditions; still others operate under state statutes that require accommodation. The MRO contract and the employer drug-testing policy should specify the handling protocol explicitly to avoid case-by-case inconsistency.

Hemp-derived CBD, Delta-8 isomers, and confirmed-positive cross-contamination

The 2018 Agriculture Improvement Act (Farm Bill) removed hemp — defined as cannabis containing less than 0.3 percent delta-9 THC by dry weight — from the federal controlled-substances framework. The resulting consumer market includes CBD products, Delta-8 THC isomer products, and a range of hemp-derived cannabinoid products marketed as federally legal. FDA has maintained a cautious regulatory posture, has issued repeated warning letters about unsubstantiated health claims, and has emphasized that the hemp-derived product market is not subject to the same manufacturing and quality controls as FDA-approved pharmaceuticals.

From a testing-program standpoint, several mechanisms can produce a confirmed THC-COOH positive in a donor who reports only legal hemp-derived product use. First, manufacturing variability and contamination — a CBD product marketed as containing less than 0.3 percent delta-9 THC may, in practice, contain higher concentrations than the label states, particularly in products that have not been third-party-tested. Sustained use of such products can produce detectable urinary THC-COOH at the SAMHSA confirmation cutoff (15 ng/mL).

Second, Delta-8 THC and other hemp-derived isomers can produce in-vivo metabolic conversion to compounds that contribute to the THC-COOH analyte signal used in confirmation testing. The analytical specificity of LC-MS/MS THC-COOH targeting is not absolute against the full range of cannabinoid metabolites that may follow consumption of isomer products. Programs should consult their reference laboratory about analyte specificity and the operational implications for donors reporting hemp-derived product use.

Third, contamination and adulteration of consumer products with synthetic cannabinoid analogs has been documented in some state enforcement actions. The operational reality is that a donor cannot reliably know whether a hemp-derived product they purchase will produce a urinary THC-COOH signal at the SAMHSA cutoff. From an MRO standpoint, the standard DOT practice is to report a confirmed THC positive regardless of donor explanations about hemp-derived product use, because the analytical result is the regulatory anchor.

ADA jurisprudence summary

The Americans with Disabilities Act (ADA) prohibits employment discrimination against qualified individuals with disabilities. Federal courts and the Equal Employment Opportunity Commission have generally held that current illegal drug use — including marijuana use under federal Schedule I — is not protected under the ADA, even when the underlying medical condition for which the marijuana was recommended is itself a protected disability. The ADA explicitly excludes current illegal drug use from its definition of protected disability.

State disability-rights statutes vary considerably. Some states have enacted statutes that explicitly protect medical-cannabis cardholders from employment discrimination; some state courts have read existing disability-rights frameworks to require accommodation of off-duty medical-cannabis use; other states have decided the opposite. The jurisprudence is jurisdiction-specific and continues to evolve. Multi-state employers face the highest exposure to inconsistency.

This article does not provide legal advice. Programs evaluating medical-cannabis accommodation policy should engage employment counsel familiar with current jurisprudence in each jurisdiction of operation. The federal ADA baseline is well-established; state-level variance is the area where most operational risk concentrates.

Employer testing-policy considerations

Several policy questions deserve explicit treatment in any written drug-testing policy that may encounter THC positives. First, what is the employers position on state medical-cannabis authorizations? A policy that is silent on this question creates ambiguity that complicates both MRO handling and any subsequent adverse-action decision. Counsel should draft explicit language addressing how state authorizations are treated.

Second, what is the employers position on hemp-derived CBD and Delta-8 THC product use? A policy that prohibits all THC-positive results regardless of donor explanation creates a clearer enforcement standard but may face challenge in jurisdictions with hemp-product protections. A policy that accepts hemp-derived product use as an MRO defense creates a verification challenge — the donor cannot produce a chain-of-custody documentation that distinguishes hemp-derived from cannabis-derived THC exposure.

Third, what is the employers panel selection? Programs that test THC will encounter the full spectrum of medical-cannabis, hemp-derived, and isomer-product complexity. Programs that do not test THC — increasingly common in non-safety-sensitive private employment in cannabis-legal states — avoid the operational complexity at the cost of giving up the THC-related insight a panel would provide. Panel-selection decisions should be made deliberately and documented.

Panel selection and operational considerations

For programs that include THC in their testing panel, the analytical workflow is the standard immunoassay-screen plus LC-MS/MS-confirm pathway. The SAMHSA cutoffs are 50 ng/mL for urinary immunoassay screening and 15 ng/mL for LC-MS/MS confirmation of THC-COOH. These cutoffs were calibrated for the analytical environment that predated the current hemp-derived product market and remain the regulatory anchor for federal testing frameworks.

Non-federal programs may select higher or lower cutoffs based on their use case. Higher cutoffs reduce the rate of confirmed positives from passive exposure and trace contamination but reduce sensitivity to lower-level recent use. Lower cutoffs increase sensitivity at the cost of higher confirmed-positive rates and additional MRO workload. Cutoff selection should be discussed with the reference laboratory and documented in the written testing policy.

Oral-fluid THC testing has become more common in workplace contexts because the recent-use detection window (typically 24-48 hours for oral fluid versus weeks for urine) aligns more closely with the operational question most employers actually want to answer — whether the donor was impaired or recently exposed at the time of incident or shift. For post-accident and reasonable-suspicion testing in particular, oral fluid offers operational advantages over urine for THC. The analytical interpretation of THC oral-fluid results requires the same MRO and counsel framework as urinary testing.

Specimen-validity testing remains essential regardless of panel selection. Standard validity testing — creatinine, specific gravity, urinary pH, and oxidant/nitrite checks — protects the integrity of the THC result along with the rest of the panel. Specimens flagged as dilute, substituted, adulterated, or invalid are reported separately and typically trigger recollection under direct observation per written policy.

Documentation and adverse-action discipline

Any adverse action arising from a confirmed THC positive — whether under a federal mandate or an employer policy — should be documented with the same chain-of-custody and procedural discipline as any other testing-related decision. The collection record, the chain-of-custody form, the laboratory report, the MRO review and verification, and any donor explanation submitted should all be retained according to the records-retention requirements applicable to the program type.

For DOT-covered employers, 49 CFR Part 40 records-retention requirements apply (five years for verified positives and refusals, one year for negative and canceled results, with specific subcategory rules). For non-DOT employers, retention requirements are set by counsel based on jurisdiction-specific statutes of limitation and any applicable contract or collective-bargaining obligations. The retention period should be specified in the written drug-testing policy.

Programs that anticipate medical-cannabis-related disputes — whether MRO defense disputes, ADA-related accommodation requests, or state-statute-based challenges — benefit from documenting policy decisions, training records, and any counsel-driven analyses contemporaneously with the underlying decisions. After-the-fact documentation is materially less defensible than contemporaneous policy and procedural records.